Autonomix Medical (NASDAQ:AMIX) Cut to Strong Sell at Wall Street Zen

Wall Street Zen downgraded shares of Autonomix Medical (NASDAQ:AMIX) to a strong sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

AMIX has been the topic of a number of other research reports. Weiss Ratings upgraded Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Zacks Research raised Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Autonomix Medical currently has a consensus rating of “Hold” and an average target price of $42.00.

Autonomix Medical Price Performance

NASDAQ AMIX opened at $4.83 on Friday. The company has a market capitalization of $4.69 million, a PE ratio of -0.12 and a beta of -1.16. The company has a fifty day moving average of $6.28 and a 200 day moving average of $7.52. Autonomix Medical has a 1 year low of $2.44 and a 1 year high of $32.55.

Autonomix Medical (NASDAQ:AMIX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($5.02) EPS for the quarter, beating the consensus estimate of ($6.40) by $1.38. Research analysts expect that Autonomix Medical will post -20.17 earnings per share for the current year.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.